90yttrium colloid for Cystic Tumors of the Sellar/Parasellar Region

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
Cystic Tumors of the Sellar/Parasellar Region
90yttrium colloid - Radiation
Eligibility
Any Age
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test the safety and effectiveness of a new treatment for cystic pituitary lesions. The treatment is the stereotactic intracavitary instillation of 90yttrium colloid, and it will be compared to the other available treatment options.

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Other trials for Cystic Tumors of the Sellar/Parasellar Region

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Within 3 weeks of treatment

12 months after treatment
Cyst shrinkage
Week 3
Localization of intracystic 90yttrium colloid by PET-CT

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Other trials for Cystic Tumors of the Sellar/Parasellar Region

Trial Design

1 Treatment Group

90yttrium colloid
1 of 1
Experimental Treatment

40 Total Participants · 1 Treatment Group

Primary Treatment: 90yttrium colloid · No Placebo Group · Phase 3

90yttrium colloid
Radiation
Experimental Group · 1 Intervention: 90yttrium colloid · Intervention Types: Radiation

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: within 3 weeks of treatment

Who is running the clinical trial?

David ClarkeLead Sponsor
1 Previous Clinical Trials
1 Total Patients Enrolled

Eligibility Criteria

Age Any Age · All Participants · 9 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a cystic sellar, suprasellar, parasellar or intrasellar mass.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 11th, 2021

Last Reviewed: October 6th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.